Founded and hosted by CQDM, CATALIS is the materialization of the Early Stage Clinical Trials (ESCT) initiative in Quebec. Initiated by Montreal InVivo, CQDM and three founding academic centres (the Centre hospitalier de l’Université de Montréal, the McGill University Health Centre and the Sainte-Justine Mother and Child University Hospital Centre), this vast project is designed to position Quebec as a global leader in clinical research.
To achieve its objectives of doubling private investments in Quebec’s early stage clinical trials by 2022, CATALIS partners have developed a 5-year action plan aimed essentially at optimizing the operational processes of clinical research healthcare institutions, and to promote their expertise worldwide.
The early clinical trial initiative in Quebec brings together all stakeholders involved in early clinical research in Quebec, including Quebec health institutions, the pharmaceutical industry, contract research organizations, economic development organizations, other initiatives dedicated to improving the clinical research environment, as well as CATALIS Quebec, a non-profit organization which acts as the coordinating office for the initiative. More specifically, CATALIS Quebec’s main mandate is to engage clinical research stakeholders in Quebec, coordinate the initiative’s joint projects, as well as promote Quebec’s expertise and excellence in early stage clinical research worldwide.
CATALIS benefits from the financial support of the Government of Quebec through the “Stratégie québécoise des sciences de la vie 2017-2027”, and of the following organizations: GlaxoSmithKline, Pfizer, Takeda, Abbvie, Merck, Servier, the Fonds de recherche du Québec – Santé, and Innovative Medicines Canada. For more information on the early clinical trial initiative in Quebec, visit www.catalisquebec.com.